# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Single Technology Appraisal

## Depemokimab for treating severe eosinophilic asthma in people 12 years and over ID6447

## Provisional Stakeholder List

| Provisional Consultees | Provisional Commentators (no right to submit or appeal) |
|---|---|
| Company<br>• GlaxoSmithKline (depemokimab)<br><br>Patient/carer groups<br>• Allergy UK<br>• Asthma + Lung UK<br>• Asthma Relief Charity<br>• Asthma Trust for Asthmatic Children<br>• European Federation of Allergy & Airways Diseases Patient Association<br>• Fifth Sense<br>• NARA - The Breathing Charity<br>• South Asian Health Foundation<br>• Specialised Healthcare Alliance<br>• The Samter's Society<br><br>Healthcare professional groups<br>• Association for Respiratory Technology and Physiology<br>• Association of Respiratory Nurse Specialists<br>• British Geriatrics Society<br>• British Paediatric Respiratory Society<br>• British Rhinological Society<br>• British Thoracic Society<br>• ILD-IN: Interstitial Lung Diseases Interdisciplinary Network<br>• National Heart and Lung Institute<br>• Neonatal and Paediatric Pharmacists Group<br>• Primary Care Respiratory Society UK<br>• Royal College of General Practitioners<br>• Royal College of Nursing<br>• Royal College of Paediatrics & Child Health | General<br>• All Wales Therapeutics and Toxicology Centre<br>• Allied Health Professionals Federation<br>• Board of Community Health Councils in Wales<br>• British National Formulary<br>• Care Quality Commission<br>• Department of Health - Northern Ireland<br>• Healthcare Improvement Scotland<br>• Medicines and Healthcare products Regulatory Agency<br>• National Association of Primary Care<br>• National Pharmacy Association<br>• NHS Confederation<br>• Scottish Medicines Consortium<br>• Welsh Government<br>• Welsh Health Specialised Services Committee<br><br>Possible comparator companies<br>• AstraZeneca, (benralizumab, tezepelumab)<br>• Novartis (omalizumab)<br>• Sanofi (dupilumab)<br>• TEVA UK (reslizumab)<br><br>Relevant research groups<br>• Asthma, Allergy and Inflammation Research Charity<br>• British Association for Lung Research<br>• Cochrane Airways Group<br>• Genomics England<br>• MRC Clinical Trials Unit<br>• National Institute for Health Research |


 

| **Provisional Consultees** | **Provisional Commentators (no right to submit or appeal)** |
|---|---|
| • Royal College of Pathologists<br>• Royal College of Physicians<br>• Royal Pharmaceutical Society<br>• Royal Society of Medicine<br>• UK Clinical Pharmacy Association<br><br><u>Others</u><br>• Department of Health and Social Care<br>• NHS England | <u>Associated Public Health groups</u><br>• Public Health Wales<br>• UK Health Security Agency |

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

**Definitions:**

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

<u>Consultees</u>

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

<u>Commentators</u>

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare


 

Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.


 